We designed the EURAMOS-1 trial to investigate whether intensified .. and a normal creatinine concentration for their age as per protocol. EURAMOS-1, an international randomised study for osteosarcoma: Results from Pre-operative chemotherapy was completed according to protocol in 94%. The EURAMOS 1 trial is a multimodal therapy of osteosacoma with precluding treatment with protocol chemotherapy (for example HIV.
|Published (Last):||15 April 2008|
|PDF File Size:||20.58 Mb|
|ePub File Size:||1.60 Mb|
|Price:||Free* [*Free Regsitration Required]|
It is permissible to administer up to two additional MTX courses and have the patient remain eligible for randomization.
Greater patient involvement at the design stage may help in the future. Registered patients were offered randomisation when also had: Granulocyte growth factors were recommended but not mandated.
EURAMOS-1 is an academic clinical trial funded through multiple national and international government agencies and cancer charities see http: Long-term event data were sought in all patients, regardless of randomisation.
Excludes three deaths occurred after surgery.
Helmke23 P. This was the background against which we joined together to attempt to develop new paradigms for treating this disease. The role of interferons in the treatment of osteosarcoma. Treatment will be allocated using permuted blocks, stratified by group, site of primary tumor and presence of metastases.
Dexrazoxane could be used at investigators’ discretion for reduced cardiac function remaining in the normal range; this applied throughout in North America but was withdrawn by the European Medicines Agency in It assessed maintenance therapy in patients with a better prognosis Good Response [ 19 ] and intensification in patients with poorer prognosis Poor Response [ 920 — 22 ].
Page Not Found | MRC Clinical Trials Unit at UCL
Spastic diplegia as a complication of interferon alfa-2a treatment of hemangiomas of infancy. P therapeutic intensification in non-metastatic osteosarcoma: Jundt24 L. Osteosarcoma therapy was revolutionised by the introduction of adjuvant combination chemotherapy, in the s, but has improved little since.
Response classification was dichotomised: Meyer29 P.
Whelan1 S. Thirty-one patients were deemed ineligible post-registration based on reference histological review of the biopsy. The results were further improved during the next decade, but since then, no clinically significant advances have been made in survival, although more patients access combination chemotherapy within and outside trials.
The PedsQL in pediatric cancer: Severe renal, neurological and left ventricular dysfunctions were uncommon. This was the first publicly-funded pan-European clinical trial to be activated after European countries implemented the European Clinical Trials Directive, which created new challenges [ 23 ].
These important questions were amenable to a relatively simple trial design. Therefore, this study addressed separate treatment questions based on histological response. J Natl Cancer Inst.
The primary outcome measure was event-free survival EFSdefined as time protocok randomisation to the first of: Information collected on reasons for non-randomisation has been relatively non-informative but anecdotally, young people expressed a reluctance to risk allocation to experimental treatments that were substantially longer than the standard MAP schedule. Goorin18 R. We designed a clinical trial to include patients with newly diagnosed localised or metastatic osteosarcoma see supplementary Material, available at Annals of Oncology online of the extremity or axial skeleton deemed to be suitable for complete resection of all disease sites.
Supplementary Material Supplementary Data: English translations are still in development.
Page Not Found
The pre-operative toxicities reported were as expected. We estimated accrual as a proportion of expected age-related osteosarcoma incidence osteosarcoma to address whether participation was equally likely within the study age range.
Flanagan16, 17 H.
Kuehne26 C. At the time of trial planning, few data were available to eueamos a sample size calculation to accurately estimate randomisation rates and these were markedly lower than expected, which contributed to a decision to expand registration targets from to over The two questions chosen for this first study stratified post-operative treatment according to the histologically assessed response to pre-operative chemotherapy.